Orally Administered Manganese With and Without Ascorbic Acid as a Liver-Specific Contrast Agent and Bowel Marker for Magnetic Resonance Imaging: Phase I Clinical Trial Assessing Efficacy and Safety.
OBJECTIVES:: The objectives of this clinical trial of orally administered manganese in magnetic resonance imaging (MRI) of the liver were to assess signal enhancements in the liver with and without the addition of an uptake promoter, ascorbic acid, and to evaluate acute safety. MATERIALS AND METHODS:: A total of 18 healthy adult males were enrolled in the present trial. Contrast medium: MnCl2, dos